Programme

Presentation synopsis:

STI in the era of PrEP and U=U

The incidence of sexually transmitted infections (STIs), both bacterial (due to Chlamydia trachomatis, Neisseria gonorrheae, Mycoplasma genitalium, and Treponema pallidum, and viral (due to viral hepatitis A and C and human papillomaviruses) is increasing worldwide, especially in men who have sex with men (MSM) and represent a major public health concern. Indeed, the advances in the treatment and prevention of HIV infection over the last couple of years, have led to an increase in risk compensation with less consistent use of condoms in this population. Although these high rates of STIs among MSM do not undermine PrEP efficacy against HIV or U=U, they represent a new challenge in prevention, diagnosis and treatment.


This review will address the epidemiology of STIs in the era of PrEP and U=U, different approaches that could reduce the rate of STIs, and prospects for future strategies including antibiotic prophylaxis and vaccines for STIs.

Speaker biography:

Jean-Michel Molina, MD, PhD, is Professor of Infectious Diseases at the University of Paris Diderot - Paris 7, and Head of the Infectious Diseases Department at the Saint-Louis Hospital in Paris, France. The Department of Infectious Diseases at the Saint-Louis Hospital is mainly involved in the care of immunocompromised patients, patients with HIV infection, bone marrow and renal transplant recipients, and patients with haematological malignancies and cancers.

His primary clinical research interest focuses on HIV infection, initially the treatment of AIDS-related opportunistic infections, and then the treatment of HIV infection. He has been involved in a number of studies assessing new drugs or new strategies for the treatment of HIV infection. A cohort of more than 4,000 patients with HIV infection is followed in his department. 

 

He is also a member of the French National Institute of Health and Medical Research (INSERM) U944 team at the Saint-Louis Hospital investigating cell biology of viral infections. He has authored many papers in a wide variety of scientific journals, including Clinical Infectious Diseases, the Journal of Infectious Diseases, the New England Journal of Medicine, the Lancet and AIDS.

 

He is also involved in the French National Agency for AIDS Research (ANRS), where he chaired the clinical trial group for the last 12 years before becoming a member of the ANRS strategic committee. More recently, Professor Molina has broadened his field of interest to the prevention of HIV infection with antiretrovirals and has led the ANRS IPERGAY pre-exposure prophylaxis (PrEP) trial in MSM. A cohort of more than 2,000 people on PrEP is followed in his unit, and a new ANRS PrEP study (ANRS Prevenir) is implemented in the Paris region to contain the HIV epidemic among gay men.


Registration

Registration is open

Second Announcement

Take a look

Call for abstracts

Submissions are closed